Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim sold 500,000 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $2.44, for a total transaction of $1,220,000.00. Following the transaction, the chief executive officer now owns 1,911,055 shares in the company, valued at approximately $4,662,974.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jong Joseph Kim also recently made the following trade(s):

  • On Monday, June 3rd, Jong Joseph Kim sold 2,129,553 shares of Inovio Pharmaceuticals stock. The stock was sold at an average price of $2.36, for a total transaction of $5,025,745.08.
  • On Tuesday, May 21st, Jong Joseph Kim sold 100,000 shares of Inovio Pharmaceuticals stock. The stock was sold at an average price of $3.31, for a total transaction of $331,000.00.
  • On Thursday, May 16th, Jong Joseph Kim sold 136,768 shares of Inovio Pharmaceuticals stock. The stock was sold at an average price of $3.50, for a total transaction of $478,688.00.

INO traded up $0.09 during midday trading on Tuesday, reaching $2.46. The company’s stock had a trading volume of 15,019 shares, compared to its average volume of 977,962. The stock has a market cap of $238.22 million, a PE ratio of -2.34 and a beta of 1.96. The company has a debt-to-equity ratio of 1.02, a quick ratio of 4.92 and a current ratio of 4.92. Inovio Pharmaceuticals Inc has a 1 year low of $2.15 and a 1 year high of $6.30.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01). The firm had revenue of $2.83 million during the quarter, compared to the consensus estimate of $4.44 million. Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. Equities research analysts predict that Inovio Pharmaceuticals Inc will post -1.01 EPS for the current year.

A number of brokerages have weighed in on INO. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. HC Wainwright restated a “buy” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, May 7th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Thursday, February 14th. Cantor Fitzgerald began coverage on shares of Inovio Pharmaceuticals in a report on Monday, March 25th. They issued an “overweight” rating and a $3.62 price objective on the stock. Finally, Maxim Group set a $8.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, February 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $7.22.

Several hedge funds and other institutional investors have recently modified their holdings of the company. M Holdings Securities Inc. bought a new position in shares of Inovio Pharmaceuticals in the first quarter worth approximately $54,000. BlueMountain Capital Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 199.7% in the first quarter. BlueMountain Capital Management LLC now owns 42,750 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 28,488 shares in the last quarter. Jefferies Group LLC bought a new position in shares of Inovio Pharmaceuticals in the first quarter worth approximately $106,000. Geode Capital Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 12.7% in the first quarter. Geode Capital Management LLC now owns 1,131,213 shares of the biopharmaceutical company’s stock worth $4,219,000 after buying an additional 127,118 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Inovio Pharmaceuticals by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 502,380 shares of the biopharmaceutical company’s stock worth $1,874,000 after buying an additional 11,008 shares in the last quarter. Hedge funds and other institutional investors own 47.25% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Inovio Pharmaceuticals Inc (INO) CEO Sells 500,000 Shares of Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/insider-selling-inovio-pharmaceuticals-inc-ino-ceo-sells-500000-shares-of-stock/3031356.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Recommended Story: What is the Book Value of a Share?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.